ArticleDEN open2026
The Capability of a Novel All-in-One Sphincterotome With High Rotation and a Freely Bendable Blade for Various Endoscopic Retrograde Cholangiopancreatography-Related Procedures.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to evaluate the capability of a novel all-in-one sphincterotome in various procedures related to endoscopic retrograde cholangiopancreatography (ERCP), including procedures in patients with surgically altered anatomy. Methods: A total of 108 patients who underwent ERCP using the novel all-in-one sphincterotome (ENGETSU; Kaneka Medix, Tokyo, Japan) between November 2023 and December 2024 were included in this retrospective analysis. We evaluated the success rates of bile duct cannulation and endoscopic sphincterotomy (EST) as well as the incidence of procedure-related adverse events (AEs). Results: Bile duct cannulation was performed in patients with native papillae, including 30 patients with normal anatomy, three with Billroth I reconstruction, one with Billroth II reconstruction, and six with Roux-en-Y reconstruction. The overall cannulation success rate was 72.5%, with a median cannulation time of 3 min. EST was performed in 65 patients with normal anatomy, three with Billroth I reconstruction, and 13 with Roux-en-Y reconstruction, with an overall success rate of 98.8%. Procedure-related AEs were observed in four patients with post-ERCP pancreatitis, three with post-EST bleeding, and one with cholangitis; all patients recovered and were discharged. Among 14 patients in whom deep biliary cannulation failed when using the conventional ERCP cannula, subsequent use of the novel device during second-line cannulation led to successful cannulation in 13 patients (92.9%). Conclusion: The novel all-in-one sphincterotome demonstrated the capability to perform various ERCP-related procedures, including in patients with surgically altered anatomy. Trial Registration: UMIN000058337.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.